Skip to main content

Evolus, Inc.

EOLS
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001570562

In the last 90 days, Evolus, Inc. insiders filed 0 open-market purchases and 1 sale; 158 institutions reported holding it in 13F filings for Q2 2026, worth $384.6M in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Evolus, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
1 filing
1 insider, $950.0K in total
Insiders trading
1
Net value
−$950.0K
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Evolus, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Evolus, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Moatazedi DavidSee Remarks499,592Sep 4, 20265
Avelar RuiSee Remarks427,423Mar 20, 20264
Gill David NDirector86,887Feb 19, 20261
White Albert G IIIDirector95,937Feb 19, 20261
Parschauer Karah HerdmanDirector77,742Feb 19, 20261
Malik VikramDirector321,109Feb 19, 20261
Stewart BradyDirector134,188Feb 19, 20261
Mitchell TatjanaChief Financial Officer226,092Feb 19, 20262
Yamagishi-Dressler TomokoChief Marketing Officer89,949Aug 26, 20250
Beaver SandraChief Financial Officer167,089May 14, 20250
Blank SimoneDirector77,111Mar 11, 20250
Hayman RobertDirector54,856Feb 9, 20240
Medytox Inc.Other: Former 10% Owner3,381,326Oct 18, 20230
Alphaeon 1 LLC10% Owner4,214,871Feb 22, 20230
Farrell Peter CDirector43,174Jan 31, 20230
Silvernail Lauren PSee Remarks141,571May 18, 20220
Muilenburg CrystalChief Marketing Officer134,248Mar 10, 20220

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Sep 4, 2026 (view filing)7:04 PM ETSep 22 daysMoatazedi DavidSee RemarksSSale−105.1K$9.04−$950.0K−17.4%499.6K after
Mar 20, 2026 (view filing)Mar 20Same dayAvelar RuiSee RemarksSSale−3.12K$4.75−$14.8K−0.7%427.4K after
Mar 20, 2026 (view filing)Mar 20Same dayMoatazedi DavidSee RemarksSSale−13.7K$4.75−$64.9K−2.2%604.7K after10b5-1
Mar 18, 2026 (view filing)Mar 171 dayMoatazedi DavidSee RemarksSSale−116.7K$4.89−$570.8K−15.9%618.4K after10b5-1
Mar 18, 2026 (view filing)Mar 171 dayAvelar RuiSee RemarksSSale−30.0K$4.89−$146.7K−6.5%430.5K after10b5-1
Dec 29, 2025 (view filing)Dec 227 daysMoatazedi DavidSee RemarksSSale−10.5K$7.15−$75.4K−2.9%354.4K after10b5-1
Dec 29, 2025 (view filing)Dec 227 daysAvelar RuiSee RemarksSSale−2.26K$7.15−$16.2K−0.6%356.8K after10b5-1
Aug 26, 2025 (view filing)Aug 224 daysYamagishi-Dressler TomokoChief Marketing OfficerSSale−5.72K$7.51−$43.0K−6.0%89.9K after10b5-1
Aug 18, 2025 (view filing)Aug 153 daysStewart BradyDirectorPPurchase+30.0K$6.82+$204.6K+51.2%88.6K after
Jun 16, 2025 (view filing)Jun 13-163 daysMoatazedi DavidSee RemarksSSale−127.9K$10.03−$1.28M−26.0%364.9K after2 lots
Jun 10, 2025 (view filing)Jun 91 dayWhite Albert G IIIDirectorPPurchase+20.0K$9.45+$189.0K+65.8%50.4K after
May 14, 2025 (view filing)May 122 daysAvelar RuiSee RemarksSSale−3.38K$9.87−$33.4K−0.9%359.1K after10b5-1
May 14, 2025 (view filing)May 131 dayBeaver SandraChief Financial OfficerSSale−6.49K$10.02−$65.1K−3.7%167.1K after10b5-1
May 14, 2025 (view filing)May 122 daysMoatazedi DavidSee RemarksSSale−15.8K$9.87−$155.8K−3.1%492.8K after10b5-1
Mar 28, 2025 (view filing)Mar 271 dayMoatazedi DavidSee RemarksSSale−6.25K$12.40−$77.5K−1.2%508.6K after10b5-1
Mar 20, 2025 (view filing)Mar 182 daysAvelar RuiSee RemarksSSale−27.9K$13.26−$370.0K−7.1%362.5K after10b5-1
Mar 20, 2025 (view filing)Mar 182 daysBeaver SandraChief Financial OfficerSSale−9.00K$13.26−$119.3K−4.9%173.6K after10b5-1
Mar 20, 2025 (view filing)Mar 182 daysYamagishi-Dressler TomokoChief Marketing OfficerSSale−4.54K$13.26−$60.1K−4.5%95.7K after10b5-1
Mar 20, 2025 (view filing)Mar 182 daysMoatazedi DavidSee RemarksSSale−103.4K$13.26−$1.37M−16.7%514.9K after10b5-1
Mar 14, 2025 (view filing)Mar 122 daysParschauer Karah HerdmanDirectorSSale−12.9K$12.99−$167.4K−28.6%32.2K after
Dec 26, 2024 (view filing)Dec 233 daysAvelar RuiSee RemarksSSale−2.25K$10.85−$24.4K−0.6%366.6K after10b5-1
Dec 26, 2024 (view filing)Dec 233 daysBeaver SandraChief Financial OfficerSSale−1.59K$10.85−$17.2K−1.1%146.9K after10b5-1
Dec 26, 2024 (view filing)Dec 233 daysMoatazedi DavidSee RemarksSSale−10.5K$10.85−$113.9K−2.0%522.8K after10b5-1
Sep 6, 2024 (view filing)Sep 6Same dayBeaver SandraChief Financial OfficerSSale−3.28K$14.98−$49.1K−2.2%148.5K after
Sep 4, 2024 (view filing)Aug 305 daysYamagishi-Dressler TomokoChief Marketing OfficerSSale−5.63K$15.85−$89.3K−6.4%82.4K after
Jun 6, 2024 (view filing)Jun 4-62 daysMoatazedi DavidSee RemarksSSale−471.4K$12.74−$6.01M−46.9%533.3K after3 lots
Jun 5, 2024 (view filing)Jun 32 daysMalik VikramDirectorSSale−7.50K$12.96−$97.2K−3.0%246.5K after
May 15, 2024 (view filing)May 13-142 daysGill David NDirectorSSale−10.4K$12.64−$131.0K−23.4%34.0K after2 lots
May 15, 2024 (view filing)May 132 daysMalik VikramDirectorSSale−28.0K$12.93−$362.0K−9.9%254.0K after
May 14, 2024 (view filing)May 104 daysMoatazedi DavidSee RemarksSSale−16.1K$12.72−$204.2K−2.3%673.6K after
May 14, 2024 (view filing)May 104 daysAvelar RuiSee RemarksSSale−3.44K$12.72−$43.8K−0.9%368.8K after
May 14, 2024 (view filing)May 104 daysBeaver SandraChief Financial OfficerSSale−2.42K$12.72−$30.8K−1.6%151.8K after
Mar 29, 2024 (view filing)Mar 272 daysMoatazedi DavidSee RemarksSSale−6.24K$13.86−$86.4K−0.9%689.6K after
Mar 21, 2024 (view filing)Mar 192 daysAvelar RuiSee RemarksSSale−27.6K$13.92−$384.2K−6.9%372.3K after
Mar 21, 2024 (view filing)Mar 192 daysBeaver SandraChief Financial OfficerSSale−5.67K$13.92−$79.0K−3.5%154.2K after
Mar 21, 2024 (view filing)Mar 192 daysMoatazedi DavidSee RemarksSSale−96.6K$13.92−$1.34M−12.2%695.9K after
Feb 23, 2024 (view filing)Feb 221 dayMoatazedi DavidSee RemarksSSale−7.71K$13.08−$100.8K−1.0%792.4K after10b5-1
Feb 23, 2024 (view filing)Feb 221 dayAvelar RuiSee RemarksSSale−1.82K$13.08−$23.8K−0.5%399.9K after10b5-1
Feb 23, 2024 (view filing)Feb 221 dayBeaver SandraChief Financial OfficerSSale−1.82K$13.08−$23.8K−1.1%159.9K after10b5-1
Feb 2, 2024 (view filing)Jan 303 daysLateParschauer Karah HerdmanDirectorSSale−11.9K$13.14−$156.8K−27.6%31.2K after10b5-1
Dec 8, 2023 (view filing)Dec 6-82 daysMoatazedi DavidSee RemarksSSale−82.6K$9.95−$822.7K−12.0%603.9K after2 lots
Oct 18, 2023 (view filing)Oct 162 daysMedytox Inc.Other: Former 10% OwnerSSaleCommon Stock, $0.00001 par value per share−1.69M$7.50−$12.7M−33.3%3.38M after
Sep 8, 2023 (view filing)Sep 62 daysBeaver SandraChief Financial OfficerSSale−3.18K$9.70−$30.8K−2.7%113.4K after10b5-1
Aug 16, 2023 (view filing)Aug 16Same dayAvelar RuiSee RemarksSSale−2.21K$10.27−$22.7K−0.6%353.4K after10b5-1
Aug 16, 2023 (view filing)Aug 16Same dayBeaver SandraChief Financial OfficerSSale−2.21K$10.27−$22.7K−1.9%116.5K after10b5-1
Aug 16, 2023 (view filing)Aug 16Same dayMoatazedi DavidSee RemarksSSale−14.8K$10.27−$151.8K−2.1%686.6K after10b5-1
Aug 15, 2023 (view filing)Aug 15Same dayMalik VikramDirectorPPurchase+175.0K$7.41+$1.30M+174.0%275.6K after
Mar 29, 2023 (view filing)Mar 272 daysMoatazedi DavidSee RemarksSSale−6.11K$8.47−$51.8K−1.0%609.6K after10b5-1
Mar 16, 2023 (view filing)Mar 142 daysMoatazedi DavidSee RemarksSSale−64.2K$8.47−$543.9K−9.4%615.7K after
Mar 16, 2023 (view filing)Mar 142 daysAvelar RuiSee RemarksSSale−14.9K$8.47−$126.3K−4.2%335.9K after